AU764681C - Stimulating neutrophil function to treat inflammatory bowel disease - Google Patents

Stimulating neutrophil function to treat inflammatory bowel disease

Info

Publication number
AU764681C
AU764681C AU34871/00A AU3487100A AU764681C AU 764681 C AU764681 C AU 764681C AU 34871/00 A AU34871/00 A AU 34871/00A AU 3487100 A AU3487100 A AU 3487100A AU 764681 C AU764681 C AU 764681C
Authority
AU
Australia
Prior art keywords
disease
crohn
patient
colony stimulating
stimulating factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU34871/00A
Other languages
English (en)
Other versions
AU3487100A (en
AU764681B2 (en
Inventor
Brian Dieckgraefe
Joshua Korzenick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St. Louis
Original Assignee
University of Washington
Washington University in St. Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Washington University in St. Louis filed Critical University of Washington
Publication of AU3487100A publication Critical patent/AU3487100A/en
Application granted granted Critical
Publication of AU764681B2 publication Critical patent/AU764681B2/en
Publication of AU764681C publication Critical patent/AU764681C/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silicon Compounds (AREA)
  • Studio Devices (AREA)
  • Treatment Of Sludge (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU34871/00A 1999-02-12 2000-02-11 Stimulating neutrophil function to treat inflammatory bowel disease Ceased AU764681C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11984299P 1999-02-12 1999-02-12
US60/119842 1999-02-12
PCT/US2000/003407 WO2000047195A1 (en) 1999-02-12 2000-02-11 Stimulating neutrophil function to treat inflammatory bowel disease

Publications (3)

Publication Number Publication Date
AU3487100A AU3487100A (en) 2000-08-29
AU764681B2 AU764681B2 (en) 2003-08-28
AU764681C true AU764681C (en) 2005-07-07

Family

ID=22386711

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34871/00A Ceased AU764681C (en) 1999-02-12 2000-02-11 Stimulating neutrophil function to treat inflammatory bowel disease

Country Status (7)

Country Link
EP (1) EP1150666B1 (cg-RX-API-DMAC7.html)
JP (2) JP2002536404A (cg-RX-API-DMAC7.html)
AT (1) ATE446767T1 (cg-RX-API-DMAC7.html)
AU (1) AU764681C (cg-RX-API-DMAC7.html)
CA (1) CA2367575A1 (cg-RX-API-DMAC7.html)
DE (1) DE60043216D1 (cg-RX-API-DMAC7.html)
WO (1) WO2000047195A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500418B1 (en) * 1999-02-12 2002-12-31 The Washington University Stimulating neutrophil function to treat inflammatory bowel disease
WO2004100972A1 (ja) * 2003-05-16 2004-11-25 Kyowa Hakko Kogyo Co., Ltd. 組織破壊を伴う疾患の予防及び／または治療剤
WO2005084702A1 (ja) * 2004-03-02 2005-09-15 Hokkaido Technology Licensing Office Co., Ltd. 臓器線維症予防・治療剤
WO2007134907A2 (en) * 2006-05-18 2007-11-29 Bayer Schering Pharma Aktiengesellschaft Gm-csf gene therapy for treatment of crohn's disease using an improved regulated expression system

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) * 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
ES8701226A1 (es) * 1984-07-06 1986-11-16 Sandoz Ag Procedimiento de obtencion de una proteina de factor estimu-lante de colonias (csf) en primates
ZA856108B (en) * 1984-10-29 1986-10-29 Immunex Corp Cloning of human granulocyte-macrophage colony simulating factor gene
AU602097B2 (en) * 1987-06-25 1990-09-27 Immunex Corporation Bovine granulocyte-macrophage colony stimulating factor
US4961926A (en) * 1987-11-19 1990-10-09 Sloan-Kettering Institute For Cancer Research Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor
US5654186A (en) * 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
US5767156A (en) * 1993-10-06 1998-06-16 Peptide Technology Limited Polyunsaturated fatty acids and uses thereof
US5733915A (en) * 1995-03-30 1998-03-31 Glaxo Wellcome Inc. Use of azathioprine to treat crohn's disease
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
CA2285923C (en) * 1997-04-01 2013-03-12 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
DE19835080A1 (de) * 1998-07-27 2000-02-03 Doecke Wolf Dietrich Mittel zur Behandlung des Krankheitsbildes Morbus Crohn

Also Published As

Publication number Publication date
AU3487100A (en) 2000-08-29
EP1150666A1 (en) 2001-11-07
ATE446767T1 (de) 2009-11-15
JP2005225890A (ja) 2005-08-25
JP2002536404A (ja) 2002-10-29
EP1150666A4 (en) 2003-07-02
WO2000047195A1 (en) 2000-08-17
DE60043216D1 (de) 2009-12-10
CA2367575A1 (en) 2000-08-17
AU764681B2 (en) 2003-08-28
EP1150666B1 (en) 2009-10-28

Similar Documents

Publication Publication Date Title
Cooke et al. Crohn's disease: course, treatment and long term prognosis
Teixeira et al. Role of the peripheral renin profile in predicting blood pressure control after bilateral nephrectomy in renal-transplanted patients.
KOSAKA et al. Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn's disease
US7641894B2 (en) Stimulating neutrophil function to treat inflammatory bowel disease
AU764681B2 (en) Stimulating neutrophil function to treat inflammatory bowel disease
AU2001279235A1 (en) Stimulating neutrophil function to treat inflammatory bowel disease
Sands et al. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease
Yamamoto et al. Granulocyte-colony stimulating factor-induced vasculitis successfully treated with short-term corticosteroid therapy: a case report
Ohashi et al. Cytomegalovirus colitis following immunosuppressive therapy for lupus peritonitis and lupus nephritis
Kusaka et al. Adsorptive monocyte‐granulocytapheresis (M‐GCAP) for refractory Crohn's disease
Sasaki et al. Leukocytapheresis therapy for severe ulcerative colitis
US20230330054A1 (en) Method for preventing or treating lung infection and lung inflammation
Schultz et al. Intestinal pseudo-obstruction related to using verapamil
US20070141053A1 (en) Treatment of inflammatory respiratory diseases
Mahvi et al. Chronic disseminated histoplasmosis in an apparently immuno-competent Belgian patient
Gomes et al. The Silent Duo: Latent Tuberculosis Complicating Takayasu Arteritis in a Young Bangladeshi Woman
Jin et al. A case of secondary bloodthirsty syndrome in Still's disease in adults
RU2119799C1 (ru) Способ лечения ботулизма
Nurcahya et al. Clinical approach and diagnosing ulcerative colitis in a 55 years old man patient: a case report
Petkova et al. Granulocyte collection and transfusion
EA051860B1 (ru) Способ профилактики, лечения или облегчения язвенного колита
Mahvi et al. CHROIVC DISSEMINIATED HISTOPLASMOSIS II {AN APPA RENTLY IMMUI\O-C OMPETEI\Tb EL GIAI {
Associeted Predictors of Pouchitis Following Ileal Pouch Anal Anastamosis: A Retrospective Review
Kuwauchi et al. An infected heart myxoma surgery case
Mathias et al. California-Clinical Vignette-Poster Finalist Lauren M Mathias, MD

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20031119

FGA Letters patent sealed or granted (standard patent)